Corrigendum to “A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan”(Acta Biomaterialia, (2016), 31, C, (186-196), (S1742706115302403), 10.1016/j.actbio.2015.12.002)

The authors regret to report that in the published article, Figures 7 and 8 contain images that do not correspond to the original experimental records. In Figure 7, the fluorescence distribution of DOX in the group DOX-AuNPs-GNPs (the DOX, Collagen 1 and Merged) were incorrect. In Figure 8, the Spleen image for the DOX-AuNPs-GNPs group was incorrect. These issues are due to an error during figure assembly. The corrected versions of Figures 7 and 8 are presented here along with original figure captions; the caption for Figure 7 now also contains the value of the scale bar previously missing. These corrections do not affect the results or conclusions of the study. The authors apologise for any inconvenience caused.(Figure presented) Revised Fig. 7. Fluorescence distribution of DOX in DOX, DOX-AuNPs, DOX-AuNPs-GNPs and losartan + DOX-AuNPs-GNPs groups. Tumor slices were stained with anti-Collagen I antibody. Green and red represented DOX and Collagen I, respectively. Bar represents 40 μm.(Figure presented) Revised Fig. 8. Fluorescence distribution of different formulations in normal tissue slices. Green represents DOX, blue represents nuclei and bar represents 40 μm.